Antiplatelet vs. R-tPA for acute mild ischemic stroke: A prospective, random, and open label multi-center study.
Xin-Hong WangLin TaoZhong-He ZhouXiao-Qiu LiHui-Sheng ChenPublished in: International journal of stroke : official journal of the International Stroke Society (2019)
The primary efficacy endpoint is favorable functional outcome, defined as a mRS 0-1 assessed at 90-day post-randomization.